Evidence map›Paper›PMID 37402064›Full record

ReviewCurrent allergy and asthma reports2023

Multiple Sclerosis Pathogenesis and Updates in Targeted Therapeutic Approaches.

Eleni S Vasileiou, Kathryn C Fitzgerald

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current allergy and asthma reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
7.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Eleni S VasileiouDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USA.
Kathryn C FitzgeraldDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USA. fitzgerald@jhmi.edu.ORCID 0000-0003-3137-0322
Johns Hopkins University · US

Funding

Circadian Rhythms and Sleep, Structural Neuroimaging and Depression in People with Multiple SclerosisK01MH121582 · NIMH · JOHNS HOPKINS UNIVERSITY · PI FITZGERALD, KATHRYN C. · 2019 to 2022
$675k
NIMH NIH HHS K01MH121582-01
6 · The paper itself

Abstract

purpose of reviewIn this review, we provide a comprehensive update on current scientific advances and emerging therapeutic approaches in the field of multiple sclerosis. RECENT

findingsMultiple sclerosis (MS) is a common disorder characterized by inflammation and degeneration within the central nervous system (CNS). MS is the leading cause of non-traumatic disability in the young adult population. Through ongoing research, an improved understanding of the disease underlying mechanisms and contributing factors has been achieved. As a result, therapeutic advancements and interventions have been developed specifically targeting the inflammatory components that influence disease outcome. Recently, a new type of immunomodulatory treatment, known as Bruton tyrosine kinase (BTK) inhibitors, has surfaced as a promising tool to combat disease outcomes. Additionally, there is a renewed interested in Epstein-Barr virus (EBV) as a major potentiator of MS. Current research efforts are focused on addressing the gaps in our understanding of the pathogenesis of MS, particularly with respect to non-inflammatory drivers. Significant and compelling evidence suggests that the pathogenesis of MS is complex and requires a comprehensive, multilevel intervention strategy. This review aims to provide an overview of MS pathophysiology and highlights the most recent advances in disease-modifying therapies and other therapeutic interventions.

Indexed as

Epstein-Barr Virus InfectionsMultiple SclerosisHerpesvirus 4, HumanHumansDMT in MSEBV in MSImmunomodulatory therapiesMS contributorsMS pathogenesisMS risk factorsMS therapeutic advancementsMS therapiesMultiple sclerosis

Identifiers

PMID37402064
OpenAlexW4383058344

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.